Cargando…

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer

Cancer immunotherapy has the goal of enhancing a patient’s intrinsic immune processes in order to mount a successful immune response against tumor cells. Cancer cells actively employ tactics to evade, delay, alter, or attenuate the anti-tumor immune response. Immune checkpoint inhibitors (ICIs) modu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coschi, Courtney H., Juergens, Rosalyn A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628657/ https://www.ncbi.nlm.nih.gov/pubmed/34898551 http://dx.doi.org/10.3390/curroncol28060373

Ejemplares similares

Prevalence of Thyroid Transcription Factor-1 (TTF-1)-Negative Small Cell Carcinoma and Napsin A Positivity in Small Cell Carcinoma in a Cross-Sectional Study of Lung Core Biopsies
por: Sayeda, Shahistha, et al.
Publicado: (2023)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
por: Baumjohann, Dirk, et al.
Publicado: (2021)

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017)

Immune-related adverse events of biological immunotherapies used in COVID-19
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Correction: T follicular helper cells: linking cancer immunotherapy and immune-related adverse events
Publicado: (2021)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
por: Yang, Ruoning, et al.
Publicado: (2022)

Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer
por: Green, Hannah Elizabeth, et al.
Publicado: (2021)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
por: Gao, Weitong, et al.
Publicado: (2023)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
por: Ke, Wanhai, et al.
Publicado: (2020)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer
por: Chitturi, Kalyan R., et al.
Publicado: (2019)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Imaging Biomarkers in Immunotherapy
por: Juergens, Rosalyn A., et al.
Publicado: (2016)

Rheumatological Adverse Events Following Immunotherapy for Cancer
por: Cretu, Ioana, et al.
Publicado: (2022)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
por: Wang, Yusha, et al.
Publicado: (2023)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021)

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy
por: Hu, Wei-Ting, et al.
Publicado: (2023)

Understanding the Attitudes and Beliefs of Oncologists Regarding the Transitioning and Sharing of Survivorship Care
por: Coschi, Courtney H., et al.
Publicado: (2021)

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
por: Rogado, Jacobo, et al.
Publicado: (2020)

Impact of proton pump inhibitors on the onset of gastrointestinal immune‐related adverse events during immunotherapy
por: Lasagna, Angioletta, et al.
Publicado: (2023)

(18)F‐FDG PET/CT features of immune‐related adverse events and pitfalls following immunotherapy
por: Cherk, Martin H, et al.
Publicado: (2022)

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
por: Hou, Yong-Zhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0aohunoueage7r3r8sej361obb